A randomised three arm comparison of one and two years of Herceptin v no Herceptin in women with HER2 3+ primary breast cancer who have completed adjuvant chemotherapy and radiotherapy.
PAHT - HERA Trial - @QualityFirstPAH
- Acute
- Acute > Clinical Support
- Acute > Research
- Leadership and Management
- Leadership and Management > Service Design/Innovation
- Leadership and Management > Service Design/Innovation > Service pathway improvements
- Campaigns
- Campaigns > #FabChange19